In order to understand the molecular basis of silibinin-mediated c-MYC expression regulation and metabolic reprogramming of pancreatic cancer cells, we investigated the effect of silibinin treatment on STAT3 activation, which enhances c-MYC expression [23]. Here, STAT3 is linked to familial pancreatic carcinoma.